AbCellera Biologics FY Conference Summary Company Overview - **Company**: AbCellera Biologics (NasdaqGS:ABCL) - **Date**: March 04, 2026 - **Context**: The company has evolved into a biotech-like entity, focusing on antibody-based therapeutics after investing approximately $1 billion over 13 years to develop its capabilities in drug discovery and development [4][5][6] Key Points Company Transition and Capabilities - AbCellera has developed an end-to-end capability for discovering, developing, and manufacturing antibody-based therapeutics, particularly for complex targets [4][5] - The company has successfully run over 100 drug discovery programs for major industry players, enhancing its expertise and capabilities [5] Lead Program: ABCL635 - **Indication**: Hot flashes or vasomotor symptoms (VMS) associated with menopause, affecting approximately 12 million women in the U.S. [8][9] - **Market Need**: There is a significant unmet medical need, as many women cannot tolerate or are contraindicated for hormone therapy [9][10] - **Differentiation**: ABCL635 aims to provide a safer and more convenient alternative to existing treatments, with a preference for monthly auto-injections over daily oral medications [10][11] Clinical Development - **Phase 1/2 Study**: Early data from the Phase 1 portion shows promising safety and biomarker engagement, aligning with expectations [12][13] - **Phase 2 Trial**: Set to include 80 patients in a triple-blinded, randomized, placebo-controlled design, aiming for efficacy comparable to existing small molecules [15][16] Future Plans for ABCL635 - If Phase 2 results are positive, the company plans to quickly initiate pivotal trials for both menopausal VMS and oncology indications [26][27] - The target product profile includes a focus on safety, tolerability, and convenience, with a potential timeline for Phase 3 trials in 2027 [27][28] Other Programs - **ABCL575**: An OX40L inhibitor in a competitive space, with plans for data updates by year-end 2026. The strategy includes potential partnerships for this molecule due to its competitive landscape [32][33][38] - **Pipeline Expansion**: AbCellera is advancing additional assets (ABCL688 and ABCL386) into clinical trials, with a focus on differentiation and unmet medical needs [41][42] Manufacturing and Financial Position - The company has established a GMP facility, enhancing its manufacturing capabilities and allowing for better control over the supply chain [51][52] - AbCellera is well-capitalized with approximately $700 million in cash equivalents, allowing for continued investment in its pipeline [51] Strategic Vision - By 2030, AbCellera aims to have a robust clinical pipeline with several assets in late-stage development, while remaining open to partnerships for certain programs that may have better ownership potential [56][57] Additional Insights - The company emphasizes a flexible approach to its pipeline strategy, focusing on both internal development and potential partnerships based on asset value and market conditions [55][57] - AbCellera's strategy includes a balance between advancing its own assets and considering out-licensing opportunities when beneficial [57]

Core Insights - AbCellera Biologics Inc. has transitioned into a clinical-stage biotechnology company, reporting total revenue of $75 million for 2025, with a net loss of $146 million [1][2]. Financial Performance - The company's revenue breakdown includes $27 million from partnered programs and $48 million from licensing and royalties [1]. - The reported net loss of $146 million reflects a strategic shift towards internal pipeline development, supported by a $187 million investment in R&D [2]. Clinical Pipeline Development - AbCellera's lead program, ABCL635, has advanced to Phase 2 studies for vasomotor symptoms, with a major readout expected in Q3 2026 [2]. - The second lead program, ABCL575, is currently in Phase 1 trials, with data anticipated by the end of the year [3]. Manufacturing and Supply Chain - The company is nearing completion of its own clinical manufacturing facility, which will enhance control over its supply chain and proprietary technology [3]. Strategic Focus - AbCellera is reducing transparency on partner-initiated program starts by moving to less frequent reporting, while concentrating on internal first-in-class programs in oncology and immunology [3].

AbCellera Biologics (NasdaqGS:ABCL) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAndrew Booth - CFOCarl Hansen - President and CEOMalcolm Hoffman - VP of BioPharma Equity ResearchSarah Noonberg - Chief Medical OfficerStephen Willey - Managing Director of HealthcareTryn Stimart - Chief Legal and Compliance OfficerConference Call ParticipantsAllison Bratzel - VP and Senior Research AnalystBrendan Smith - Director and Senior Analyst for Life Science Tools and Diagnostics/Biotechnolog ...

Financial Data and Key Metrics Changes - Revenue for the year was $75 million, a significant increase from approximately $29 million in 2024, with $36 million stemming from settling patent infringement claims against Bruker [16][17] - The net loss for the year was roughly $146 million, an improvement compared to a loss of about $163 million in the previous year, resulting in a loss of $0.49 per share [17][19] - The company finished the year with approximately $561 million in cash and equivalents, and with roughly $140 million in available committed government funding, totaling around $700 million in available liquidity [19][20] Business Line Data and Key Metrics Changes - The pipeline expanded from two preclinical programs at the beginning of the year to four clinical programs by year-end, with ABCL635 advancing to a randomized, double-blind, phase II study [7][11] - The company initiated work on one additional partner-initiated program, bringing the cumulative total to 104 programs with downstream participation [12][14] Market Data and Key Metrics Changes - The company anticipates two clinical readouts in 2026 and aims to have five clinical stage programs across various large market indications by mid-2027 [10][11] - The focus on internal programs is expected to lead to lower research fee revenues as the company prioritizes its proprietary pipeline [16] Company Strategy and Development Direction - The company aims to transition into a vertically integrated clinical-stage biotech, focusing on building its pipeline rather than its platform [5][6] - Key priorities for 2026 include delivering top-line readouts for ABCL635 phase II and ABCL575 phase I studies, advancing ABCL688 and ABCL386 through IND-enabling activities, and adding one new development candidate [11][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the integrated platform and competitive advantage in antibody discovery and development, with a focus on executing the strategy with available capital [6][12] - The company acknowledges the uncertainty in drug development but remains committed to advancing its pipeline, particularly with ABCL635, which has the potential for blockbuster status [9][10] Other Important Information - The company has made substantial investments in property, plant, and equipment to establish clinical manufacturing capabilities, which are now substantially complete [18] - The clinical manufacturing facility is expected to improve supply chain control, flexibility, and protect intellectual property [18] Q&A Session Summary Question: Potential for ABCL575 as a combination regimen - Management believes OX40 ligand has a broad effect on the immune system and is considering combination strategies with external parties [24][25] Question: Oncology-based VMS studies - Management sees opportunities in breast and prostate cancer patients experiencing severe hot flashes and believes safety and convenience will differentiate their product [29][30] Question: Target engagement data for ABCL635 - The phase I safety and target engagement data will be released alongside the phase II data in Q3 [34][35] Question: Clinical trial infrastructure capacity - The company has reshaped its internal resources to support multiple clinical programs and is committed to ensuring adequate operational capacity [47][48] Question: Decision factors for ABCL575 development - The decision will largely depend on external factors, including partnership opportunities and the competitive landscape [49][50]

AbCellera Biologics (NasdaqGS:ABCL) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Speaker4Good afternoon, and welcome to AbCellera's full year 2025 business update conference call. My name is Chelsea, and I will facilitate the audio portion of today's interact. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. At this time, I would like to turn ...

FULL YEAR 2025 BUSINESS UPDATE FEBRUARY 24, 2026 COPYRIGHT © ABCELLERA This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including ...

Core Thesis - AbCellera Biologics Inc. is transitioning from a service-oriented antibody discovery platform to a clinical-stage biotech with proprietary drug candidates, aiming to create long-term value through internal and co-developed programs [3][4] Financial Overview - As of January 21st, AbCellera's share was trading at $3.6200, with a trailing P/E of 19.92 [1] - The company holds approximately $520 million in cash and around $680 million in total liquidity, providing a strong financial position to execute its strategy without near-term financing risk [4] Market Position and Strategy - The stock has seen a decline of over 90% from its post-IPO highs, currently trading near $4.50, reflecting skepticism about the platform's ability to translate discovery into drugs rather than a deterioration of underlying assets [4] - AbCellera's internal pipeline includes Phase 1 assets ABCL635 and ABCL575, targeting large markets with differentiated dosing profiles, with initial clinical readouts expected in 2026 [5] Growth Potential - The company has a diversified royalty portfolio with over 100 partnered programs, 18 of which are in the clinic, providing long-duration upside with limited incremental capital [6] - The combination of deep liquidity, validated technology, and an expanding internal pipeline creates a compelling asymmetric opportunity for substantial upside from current depressed levels [7]

Company Overview - AbCellera is a biotechnology company headquartered in Vancouver, Canada, with approximately 500 employees, and additional facilities in Sydney, Australia, and a clinical development group in Montreal, Canada [3] - The company was founded in 2012 from an academic lab at the University of British Columbia [3] Leadership and Future Outlook - CEO Carl Hansen provided insights into the company's growth and future potential, emphasizing a transition from a technology and platform-based focus to a clinical company with multiple assets [2] - The next 6 to 18 months are expected to be significant for the company, with upcoming developments in their portfolio and promising readouts [2]

Core Insights - AbCellera Biologics Inc. (NASDAQ:ABCL) is experiencing a decline of over 23% since its fiscal Q3 2025 business update, yet analysts maintain a bullish outlook with a 12-month average price target of $8.5, indicating a potential upside of 144.96% from current levels [1]. Financial Performance - The company reported a year-over-year revenue growth of 37.62%, reaching $8.96 million, which exceeded estimates by $2.62 million. However, the earnings per share (EPS) of negative $0.19 fell short of expectations by $0.03 [3]. Strategic Direction - AbCellera is shifting its strategy from partnerships to developing its own clinical assets while still valuing existing partnerships with major pharmaceutical companies like Lilly and AbVie. This strategic pivot aims to leverage its capabilities and technologies for internal development [4]. Product Development - The company is focused on discovering and developing antibody-based medicines targeting cancer, metabolic/endocrine conditions, and autoimmune disorders, utilizing an AI-powered platform for rapid single-cell screening [5]. Analyst Ratings - On November 19, David Martin, PhD, from Bloom Burton reiterated a Buy rating with a price target of $9. Earlier, Srikripa Devarakonda from Truist Financial also maintained a Buy rating without specifying a price target [2].

Core Viewpoint - AbCellera Biologics Inc. is recommended as a Buy by Stifel Nicolaus despite reporting a wider-than-expected net loss in Q3 2024, with a price target set at $7 [1][2]. Financial Performance - The company reported a net loss of $57.1 million in Q3 2024, compared to a net loss of $51.1 million in the same quarter last year, indicating a deterioration in financial performance [2]. - Research and development (R&D) expenses increased significantly to $55 million from $41 million year-over-year [2]. - Revenue for the quarter was $9 million, up from $6.5 million in the same quarter last year, showing growth in sales [3]. Operational Highlights - AbCellera achieved key milestones, including the commencement of operations at its new clinical manufacturing facility [3]. - The company is advancing its pipeline with two lead programs, ABCL635 and ABCL575, currently in Phase 1 clinical trials [3][4]. Liquidity Position - The company ended the quarter with approximately $680 million in available liquidity, which will be utilized to execute its strategic plans and advance its clinical studies [4]. Company Overview - AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines using an integrated technology platform [5].